Medibio Share Price and Company Fundamentals
Last traded: Last Friday at 5:06 AM
Medibio Limited, a health technology company, researches, develops, and commercializes mental health technology to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. It has a clinical trial agreement with MedBridge Healthcare LLC to support sleep analysis of depressive burden (SADB) trial. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was incorporated in 1987 and is headquartered in Melbourne, Australia.
|Primary activities||Development of diagnostic heart rate variability technology for mental health diagnosis|
|Industry / Sector||Health Information Services / Healthcare|
|Mailing address||100 Albert Road Level 4 South Melbourne Melbourne VIC 3205 Australia|
|Phone / Fax||61 3 9692 7222 / 61 3 9077 9233|
|Share registry||COMPUTERSHARE INVESTOR SERVICES PTY LIMITED|
Medibio does not pay dividends.
As of Sep 2021, following are the company executives and directors listed on Medibio.
|Mr. Claude Solitario||Managing Director, CEO & Director||141.6k|
|Ms. Renee Stanton-Horne||Operations & Account Mang.|
|Ms. Stephanie Ottens||Investor Relations Director|
|Mr. Josh Purdy||PR Director|
|Dr. Michael Player||Head of Research|
|Dr. Matthew Flax||Head of Algorithm Devel. Team|
|Mr. Archie Defillo M.D.||Chief Medical Officer|
|Ms. Jennifer Solitario||Sr. VP of Corp. Health|
|Mr. Massimiliano Grassi||Head of Artificial Intelligence|
|Mr. Mathew Watkins||Joint Company Sec.|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Medibio is 14.36M and its enterprise value is 12.07M. The enterprise value to revenue ratio of MEB is 9.55.
The MEB's stocks Beta value is 1.77 making it 77% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Medibio (MEB)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Polynovo (PNV)
- Pro Medicus (PME)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Medibio (ASX:MEB) Frequently Asked Questions
1. What is Medibio's Stock Symbol?
Medibio trades on ASX under the ticker symbol "MEB".
2. What is Medibio's stock price today?
One share of MEB stock can currently be purchased for approximately $0.008.
3. How can I contact Medibio?
Medibio's mailing address is 100 Albert Road Level 4 South Melbourne Melbourne VIC 3205 Australia. The company can be reached via phone at 61 3 9692 7222.
4. What is Medibio's official website?
The official website of Medibio is http://medibio.com.au.
5. Which share registry manages Medibio's stock?
Medibio's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.